news background image

News

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
Read Article
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting
Read Article
LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development
Read Article
Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology
Read Article
DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
Read Article
Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting
Read Article
Glycotope Presents Glyco-Engineered Cell Lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium
Read Article
Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product  TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer
Read Article
Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting
Read Article
LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate
Read Article